tetano
Editor, Senior Moderator
Microb Pathog
. 2024 Aug 27:195:106893.
doi: 10.1016/j.micpath.2024.106893. Online ahead of print. Astragalus Polysaccharide improves immunogenicity of influenza vaccine as well as modulate gut microbiota in BALB/c mice
Chuanqi Wan[SUP] 1 [/SUP], Sijing Yan[SUP] 2 [/SUP], Rufeng Lu[SUP] 3 [/SUP], Chen Zhu[SUP] 3 [/SUP], Yang Yang[SUP] 3 [/SUP], Xiaowei Wu[SUP] 3 [/SUP], Zhihong Yu[SUP] 3 [/SUP], Mei Jiang[SUP] 4 [/SUP], Wei Peng[SUP] 1 [/SUP], Wenwen Song[SUP] 5 [/SUP], Haibo Wu[SUP] 6 [/SUP], Bangjiang Fang[SUP] 7 [/SUP], Yuzhou He[SUP] 8 [/SUP]
Affiliations
Background: Vaccination is the best way to prevent influenza virus infection, and insufficient antibodies make it difficult to resist influenza virus invasion. Astragalus Polysaccharide (APS) has a boosting effect on immunity, so we evaluate the effect of APS as an immune adjuvant for H1N1 influenza vaccines in this study.
Methods: The mice were immunized twice with influenza A (H1N1) vaccine and APS. Subsequently, the serum antibody levels were assessed using enzyme-linked immunosorbent assay (ELISA). The frequency of peripheral immune T cells was determined by flow cytometry. Following this, the immunized mice were exposed to a lethal dose of the virus, and changes in body weight and survival rates were recorded. Hematoxylin-eosin staining was employed to observe pathological alterations in lung and intestinal tissues. Western blot analysis was conducted to detect the expression of intestinal barrier function proteins (Occludin and Claudin-1). ELISA was utilized to measure the expression level of serum inflammatory cytokine TNF-α. Fresh mouse feces were collected after the initial immunization as well as after viral infection for 16S rRNA analysis aimed at detecting alterations in gut microbiota.
Results: Compared to the Hemagglutinin (HA) group, the APS group demonstrated higher levels of immunoglobulin G (IgG), IgG1, and IgG3, as well as neutralizing antibody levels. Additionally, it increased the frequency of CD8[SUP]+[/SUP] cells to enhance resistance against lethal infection. On day 14 post-infection, the high-dose APS group exhibited a higher survival rate (71.40 %) compared to the HA group (14.28 %), along with faster weight recovery. Furthermore, APS was found to ameliorate alveolar damage in lung tissue and rectify intestinal structural disorder. It also upregulated the expression levels of tight junction proteins Occludin and Claudin-1 in intestinal tissue while reducing serum TNF-α expression levels. In addition, populations of Colidextribacter, Peptococcaceae, and Ruminococcaceae were the dominant gut microbiota in the APS group after viral infection.
Conclusion: APS has an immune-enhancing effect and is expected to be a novel adjuvant in the H1N1 influenza vaccine.
Keywords: Adjuvant; Astragalus polysaccharide; Gut microbiota; H1N1 influenza vaccine.
. 2024 Aug 27:195:106893.
doi: 10.1016/j.micpath.2024.106893. Online ahead of print. Astragalus Polysaccharide improves immunogenicity of influenza vaccine as well as modulate gut microbiota in BALB/c mice
Chuanqi Wan[SUP] 1 [/SUP], Sijing Yan[SUP] 2 [/SUP], Rufeng Lu[SUP] 3 [/SUP], Chen Zhu[SUP] 3 [/SUP], Yang Yang[SUP] 3 [/SUP], Xiaowei Wu[SUP] 3 [/SUP], Zhihong Yu[SUP] 3 [/SUP], Mei Jiang[SUP] 4 [/SUP], Wei Peng[SUP] 1 [/SUP], Wenwen Song[SUP] 5 [/SUP], Haibo Wu[SUP] 6 [/SUP], Bangjiang Fang[SUP] 7 [/SUP], Yuzhou He[SUP] 8 [/SUP]
Affiliations
- PMID: 39197333
- DOI: 10.1016/j.micpath.2024.106893
Background: Vaccination is the best way to prevent influenza virus infection, and insufficient antibodies make it difficult to resist influenza virus invasion. Astragalus Polysaccharide (APS) has a boosting effect on immunity, so we evaluate the effect of APS as an immune adjuvant for H1N1 influenza vaccines in this study.
Methods: The mice were immunized twice with influenza A (H1N1) vaccine and APS. Subsequently, the serum antibody levels were assessed using enzyme-linked immunosorbent assay (ELISA). The frequency of peripheral immune T cells was determined by flow cytometry. Following this, the immunized mice were exposed to a lethal dose of the virus, and changes in body weight and survival rates were recorded. Hematoxylin-eosin staining was employed to observe pathological alterations in lung and intestinal tissues. Western blot analysis was conducted to detect the expression of intestinal barrier function proteins (Occludin and Claudin-1). ELISA was utilized to measure the expression level of serum inflammatory cytokine TNF-α. Fresh mouse feces were collected after the initial immunization as well as after viral infection for 16S rRNA analysis aimed at detecting alterations in gut microbiota.
Results: Compared to the Hemagglutinin (HA) group, the APS group demonstrated higher levels of immunoglobulin G (IgG), IgG1, and IgG3, as well as neutralizing antibody levels. Additionally, it increased the frequency of CD8[SUP]+[/SUP] cells to enhance resistance against lethal infection. On day 14 post-infection, the high-dose APS group exhibited a higher survival rate (71.40 %) compared to the HA group (14.28 %), along with faster weight recovery. Furthermore, APS was found to ameliorate alveolar damage in lung tissue and rectify intestinal structural disorder. It also upregulated the expression levels of tight junction proteins Occludin and Claudin-1 in intestinal tissue while reducing serum TNF-α expression levels. In addition, populations of Colidextribacter, Peptococcaceae, and Ruminococcaceae were the dominant gut microbiota in the APS group after viral infection.
Conclusion: APS has an immune-enhancing effect and is expected to be a novel adjuvant in the H1N1 influenza vaccine.
Keywords: Adjuvant; Astragalus polysaccharide; Gut microbiota; H1N1 influenza vaccine.